Damora Therapeutics, Inc. (DMRA NASDAQ) stock market data APIs
$24.6294
-0.35(-1.4%)
as of April 7, 2026
Try our APIs with
free plan!
Damora Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Prev. Close
24.6294
Open
24.2752
High
26.1666
Low
23.1519
52 wk Range
2.06-38.325
Market Cap
1 482 M
Shares Outstanding
60 303 K
EPS
2.3057
Beta
1.598
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Damora Therapeutics, Inc. data using free add-ons & libraries
Get Damora Therapeutics, Inc. Fundamental Data
Damora Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -36 540 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-20
- EPS/Forecast: -0.1079
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Damora Therapeutics, Inc. News
New
Galecto GAAP EPS of -$3.98 misses by $3.02
* Galecto press release [https://seekingalpha.com/pr/20445542-damora-therapeutics-reports-full-year-2025-financial-results-and-recent-corporate-highlights] (DMRA [https://seekingalpha.com/symbol/DMR...
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in c...
Get Damora Therapeutics, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
